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Case Study: Ticagrelor in PLATO and Prasugrel in
TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients
With Acute Coronary Syndromes
Steen Husted, MD, DSc1* and Eric Boersma, MD, PhD2
Cross-trial comparisons are typically inappropriate as there are often numerous differences in study
designs, populations, end points, and loading doses of the study drugs. These differences are clearly
reflected in the most recent updates to the European Society of Cardiology (ESC) non-ST elevation acute
coronary syndrome (NSTE-ACS) and ST elevation myocardial infarction (STEMI) guidelines, which
include recommendations for the use of the antiplatelet agents ticagrelor, prasugrel, and clopidogrel, based
in part on results from the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet
inhibitioN with prasugrel–Thrombolysis In Myocardial Infarction (TRITON-TIMI) 38, TaRgeted platelet
Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY-
ACS) and PLATelet inhibition and patient Outcomes (PLATO) trials. Here, we describe each of these trials
in detail and explain the differences between them that make direct comparisons difficult. In conclusion,
this information, along with the current guidelines and recommendations, will assist clinicians in deciding
the most appropriate treatment pathway for their patients with NSTE-ACS and STEMI.
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INTRODUCTION
In clinical practice, physicians frequently base their
decisions on data from well-controlled, randomized,
comparative clinical trials. However, these clinical de-
cisions can be difficult in the absence of head-to-head
trials that definitively demonstrate a treatment benefit
of one agent over another.
Clinical decision making based on cross-trial com-
parison is an important issue for the antiplatelet drugs
ticagrelor and prasugrel, as both have shown superi-
ority over clopidogrel in the treatment of patients
with acute coronary syndromes (ACS), but in separate
studies. There are no available data from direct
head-to-head clinical comparisons of ticagrelor and
prasugrel, although the ongoing ISAR-REACT-5 trial
(NCT01944800) aims to evaluate whether ticagrelor is
superior to prasugrel in patients with ACS for whom an
invasive treatment strategy is planned. Elsewhere,
Biondi-Zoccai et al1 undertook a clopidogrel-adjusted
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comparative meta-analysis of ticagrelor versus prasu-
grel using data from the PLATelet inhibition and patient
Outcomes (PLATO), DISPERSE-2, and TRial to assess
Improvement in Therapeutic Outcomes by optimizing
platelet inhibitioN with prasugrel–Thrombolysis In
Myocardial Infarction (TRITON-TIMI) 38 studies. The
validity of such adjusted indirect comparisons depends
on a number of factors, including the overall similarities
of the study designs, hospital setting, inclusion/exclu-
sion criteria, treatment strategies, study duration, and
end point definitions.
This review examines the similarities and differences
between the design of PLATO, TRITON-TIMI-38, and
TaRgeted platelet Inhibition to cLarify the Optimal
strateGy to medicallY manage Acute Coronary
Syndromes (TRILOGY-ACS), and assesses whether
cross-trial comparisons are appropriate in the case of
ticagrelor and prasugrel. This may help to optimize the
use of these drugs and to target treatment to the
patient populations deriving most benefit.
MAIN RESULTS OF MAJOR TRIALS
In the PLATO trial (Table 1), 18,624 patients with ACS
were randomized to ticagrelor (180 mg loading dose,
90 mg twice-daily maintenance dose) or clopidogrel
(300–600 mg loading dose, 75 mg/d maintenance
dose).2 At 12 months, ticagrelor significantly reduced
the primary end point {composite of death from vas-
cular causes, myocardial infarction [MI], or stroke
compared with clopidogrel [9.8% vs. 11.7%, respec-
tively; hazard ratio (HR): 0.84; 95% confidence interval
(CI), 0.77–0.92; P , 0.001]}. Predefined hierarchical
testing of individual secondary efficacy end points
showed ticagrelor was associated with significant re-
ductions in rates of MI (5.8% with ticagrelor vs. 6.9%
with clopidogrel, P 5 0.005), death from vascular
causes (4.0% vs. 5.1%, P 5 0.001), and death from
any cause (4.5%, vs. 5.9%, P , 0.001).2 Ticagrelor did
not increase the rate of overall major bleeding, but
a statistically significant increase in noncoronary
artery bypass grafting (non-CABG) major bleeding
(4.5% vs. 3.8%; HR: 1.19; 95% CI, 1.02–1.38; P , 0.03)
was observed.2 Dyspnea was more common in the
ticagrelor group than in the clopidogrel group (13.8%
of patients vs. 7.8%), although few patients discontin-
ued treatment due to dyspnea (0.9% vs. 0.1%) and no
effect of ticagrelor on pulmonary function was seen in
a substudy of PLATO.2,6 In the first week of treatment,
a higher incidence of ventricular pauses was observed
with ticagrelor compared with clopidogrel. However,
pauses were rarely associated with symptoms, and the
treatment groups did not differ significantly with
respect to the incidence of syncope or pacemaker
implantation.2,7 The number needed to treat (NNT)
to prevent 1 cardiovascular death, MI, or stroke in 12
months was 54.8
The TRITON-TIMI 38 trial randomized 13,608 pa-
tients with moderate-to-high-risk ACS with scheduled
percutaneous coronary intervention (PCI) to prasugrel
(60 mg loading dose, 10 mg/d maintenance dose) or
clopidogrel (300 mg loading dose, 75 mg/d mainte-
nance dose).3 At 15 months, prasugrel significantly
reduced the primary composite end point of death
from cardiovascular causes, nonfatal MI, or nonfatal
stroke compared with clopidogrel (9.9% vs. 12.1%,
respectively; HR: 0.81; 95% CI, 0.73–0.90; P , 0.001)
with an NNT within 15 months of 46.3,9 Compared
with clopidogrel, prasugrel also reduced the rates of
MI (9.7% for clopidogrel vs. 7.4% for prasugrel; P ,
0.001) and urgent target vessel revascularization (3.7%
vs. 2.5%; P , 0.001), but not death from any cause
(3.3% vs. 3.0%, P 5 0.64). There was a statistically sig-
nificant increase in non–CABG-related TIMI major
bleeding (1.8% vs. 2.4%, HR: 1.32; 95% CI, 1.03–1.68;
P 5 0.03), including fatal bleeding, with prasugrel.
In the more recent TRILOGY-ACS trial, 9326 medi-
cally managed patients (ie, without revascularization)
with unstable angina or non-ST elevation myocardial
infarction (NSTEMI) were randomized to prasugrel 10
mg/d (5 mg/d if aged $75 years or with body weight
,60 kg) or clopidogrel 75 mg/d. Clopidogrel-naive
patients who underwent randomization within 72
hours after first medical contact received a loading
dose of prasugrel 30 mg or clopidogrel 300 mg, fol-
lowed by daily blinded maintenance therapy. Patients
who did not undergo randomization within 72 hours
were treated with open-label clopidogrel before ran-
domization and then received daily maintenance
study drug. In the 7243 patients ,75 years (primary
efficacy and safety cohort), no significant difference in
the primary end point of death from vascular causes,
MI, or stroke was observed between treatment groups
over 6–30 months; no significant increase in non-
CABG major bleeding events was observed.10
A prespecified exploratory analysis of PLATO dem-
onstrated a net clinical benefit of ticagrelor, based on
time to first occurrence of any event from cardiovas-
cular death, MI, stroke, and any major bleeding event,
excluding non–life-threatening bleeding during
CABG.2,11 This composite efficacy and safety end point
demonstrated statistically significant superiority of
ticagrelor over clopidogrel for #12 months after
index ACS events (15.7% vs. 17.0%; HR: 0.92;
95% CI, 0.86–0.99; P 5 0.026). A net clinical benefit
of prasugrel over clopidogrel was also demonstrated
in TRITON-TIMI 38 for the composite of death from
Ticagrelor and Prasugrel Trials in ACS e1877
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Table 1. Summary of characteristics and outcomes from 3 major trials of antiplatelet agents (PLATO, TRITON-TIMI-38, and TRILOGY-ACS).2–4
PLATO* TRITON-TIMI 38†
TRILOGY-ACS‡
Patients ,75 yrs Overall
Type of ACS Any ACS: 43% NSTEMI, 38%
STEMI, 17% UA
ACS with scheduled PCI:
NSTEMI or UA 74%, 26%
STEMI
Medically managed:
67% NSTEMI; 33%
UA
Medically managed: 70%
NSTEMI; 30% UA
No. patients 18,624 13,608 7243 9326
Age (yrs; median) 62 61 (IQR, 53–70) 62 66
Female (%) 28 26 36 39
Symptom duration ,24 h ,72 h NSTE, ,12 h PPCI,
,14 d other STE
,10 d ,10 d
ST deviation $1 mm or
elevated biomarker at
entry (%)
89 and 86, respectively 100 Without ST-elevation Without ST-elevation
Prior MI (%) 21 18 44 43
Diabetes (%) 25 23 39 38
Major exclusion criteria Fibrinolysis ,24 h, OAC, c.i. to
CLO, drugs strongly affecting
CYP-450 3A, risk of
bradycardia
High bleeding risk, anemia,
thrombocytopenia,
intracranial disease, any
thienopyridine ,5 d
History of TIA or stroke, PCI, or CABG within previous
30 d, renal failure requiring dialysis, concomitant
OAC
Treatment A ASA, 75–100 mg (325 mg
permitted) once daily + TIC
(180 mg LD + 90 mg twice
daily 6 90 mg at PCI)
ASA, 75–162 mg once daily +
PRA (60 mg LD + 10 mg once
daily) up to 1 h post-PCI but
not before angiography
ASA, #100 mg once
daily + PRA (30 mg
LD + 5–10 mg once
daily)§
ASA, #100 mg once daily +
PRA (30 mg LD + 5 mg once
daily)§
Treatment B ASA, 75–100 mg once daily +
CLO (300 mg LD + 75 mg 6
300 mg for PCI .24 h)
ASA, 75–162 mg once daily +
CLO (300 mg LD + 75 mg
once daily) up to 1 h post-PCI
but not before angiography
ASA, #100 mg once
daily + CLO (300–600
mg LD + 75 mg once
daily)§
ASA, #100 mg once daily +
CLO (300–600 mg LD + 75 mg
once daily)§
Clopidogrel before
coronary angiography
Allowed Not allowed unless PPCI Allowed Allowed
Length of follow-up
(minimum–maximum)
Up to 12 mo (6–12, event-
driven)
Median, 14.5 mo (6–15) Not stated Median, 17.1 mo (6–30)
In-hospital PCI and use of
GPI (%), respectively
61 and 27 99 and 55 6%; % GPI use not
stated
Not stated
Use of .1 DES (%) 19 47 Not stated Not stated
CABG (%) 10 during study 2.7 during study 2 Not stated
PEEP definition CVD, NF MI, NF stroke CVD, NF MI, or NF stroke CVD, NF MI, NF stroke
PEEP in A vs. B (%) 9.8 vs. 11.7, P , 0.001 9.9 vs. 12.1, P , 0.001 13.9 vs. 16.0, P 5 0.21 18.7 vs. 20.3, P 5 0.45
(Continued on next page)
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Table 1. (Continued) Summary of characteristics and outcomes from 3 major trials of antiplatelet agents (PLATO, TRITON-TIMI-38, and TRILOGY-ACS).2–4
PLATO* TRITON-TIMI 38†
TRILOGY-ACS‡
Patients ,75 yrs Overall
Relative (absolute) risk
reduction (%)
16 (1.9) 19 (2.2) 9 (2.1) 4 (1.6)
Death in A vs. B (%) 4.5 vs. 5.9, P , 0.001 3.0 vs. 3.2 7.8 vs. 8.1, P 5 0.63 11.6 vs. 12.2, P 5 0.40
CVD in A vs. B (%) 4.0 vs. 5.1, P 5 0.001 2.1 vs. 2.4 6.6 vs. 6.8, P 5 0.48 9.9 vs. 10.2, P 5 0.38
NF MI in A vs. B (%) 5.8 vs. 6.9, P 5 0.005 7.3 vs. 9.5, P , 0.001 8.3 vs. 10.5, P 5 0.21 10.7 vs. 12.3, P 5 0.58
Definite + probable ST in
A vs. B (%)
2.2 vs. 2.9, P 5 0.02 1.1 vs. 2.4, P , 0.001 Not stated Not stated
NF stroke in A vs. B (%) 1.5 vs. 1.3 1.0 vs. 1.0 1.5 vs. 2.2, P 5 0.08 2.2 vs. 2.6, P 5 0.52
Major bleed definition¶ PLATO (and TIMI) TIMI TIMI non-CABGk TIMI non-CABGk
Major bleed in A vs. B (%) 11.6 vs. 11.2 (TIMI, 7.9 vs. 7.7) Not reported 2.1 vs. 1.5, P 5 0.27 2.5 vs. 1.8, P 5 0.29
Non-CABG major bleed in
A vs. B (%)¶
4.5 vs. 3.8 (2.8 vs. 2.2), P 5 0.03 2.4 vs. 1.8, P 5 0.03 2.1 vs. 1.5, P 5 0.27 2.5 vs. 1.8, P 5 0.29
CABG-related major bleed
in A vs. B (%)
7.4 vs. 7.9 (5.3 vs. 5.8) of all
A and B treated
13.4 vs. 3.2 of CABG treated,
P , 0.001
Not stated Not stated
Life-threatening bleed in
A vs. B (%)
5.8 vs. 5.8 (study criteria) 1.4 vs. 0.9 (non-CABG),
P 5 0.01
0.9 vs. 0.8, P 5 0.88 1.1 vs. 1.1, P 5 0.85
Intracranial bleed in A vs.
B (%)
0.3 vs. 0.2 0.3 vs. 0.3 (non-CABG) 0.7 vs. 0.5, P 5 0.39 0.8 vs. 0.7, P 5 0.42
Fatal bleed in A vs. B (%) 0.3 vs. 0.3 0.4 vs. 0.1 (non-CABG),
P 5 0.002
0.5 vs. 0.2, P 5 0.99 0.6 vs. 0.4, P 5 0.68
NNT and (non-CABG) NNH
for A vs. B
54 and 167, respectively 46 and 167, respectively NA NA
*The end point percentages are Kaplan–Meier estimates of the rate of each end point at 12 months.
†The end point percentages are Kaplan–Meier estimates of the rate of each end point at 15 months.
‡The end point percentages are Kaplan–Meier estimates of the rate of each end point at 30 months.
§Patients who underwent randomization within 72 hours after the first medical contact without previous clopidogrel treatment received a loading dose of study drug. The
prasugrel maintenance dose was 10 mg, which was adjusted to 5 mg once daily for patients who weighed ,60 kg or were aged $75 years.
¶TIMI-defined non-CABG major bleeding was the primary safety end point in TRITON-TIMI 38, but not in PLATO. However, TIMI-defined and GUSTO-defined bleeds were
also adjudicated in PLATO and are comprehensively reported by Becker et al.5
kEnd points presented use TIMI criteria for major bleeding not related to CABG. Key bleeding end points were also analyzed using GUSTO criteria for severe or life-
threatening bleeding not related to CABG.
ACS, acute coronary syndrome; ASA, aspirin; CABG, coronary artery bypass surgery; c.i., contraindication; CLO, clopidogrel; CVD, cardiovascular death; CYP, cytochrome P;
GPI, glycoprotein inhibitor; IQR, interquartile range; LD, loading dose; MI, myocardial infarction; NF, nonfatal; NNH, number needed to harm; NNT, number needed to treat;
NSTE, non-ST elevation; OAC, oral anticoagulant; PEEP, primary efficacy end point; PLATO, PLATelet inhibition and patient Outcomes; PRA, prasugrel; ST, stent throm-
bosis; STE, ST elevation; TIC, ticagrelor; TIMI, thrombolysis in myocardial infarction; TRITON, TRIal to assess improvement in Therapeutic Outcomes by optimizing platelet
iNhibition with prasugrel; UA, unstable angina.
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any cause, nonfatal MI, nonfatal stroke, and major
non-CABG bleeding (12.2% vs. 13.9%; HR: 0.87; 95%
CI, 0.79–0.95; P 5 0.004).3,9
Based on the results of these studies, ticagrelor is
indicated for the reduction of thrombotic cardiovascular
events in patients with ACS (NSTE-ACS or STEMI)
who are managed either with an ischemia-guided strat-
egy or with PCI or CABG,8,12 and prasugrel is indicated
for the reduction of thrombotic cardiovascular events
(including stent thrombosis) in patients with ACS
(NSTE-ACS or STEMI) to be managed with PCI.13 Tica-
grelor is contraindicated in patients with a history of
intracranial hemorrhage, active pathological bleeding,
severe hepatic impairment, or hypersensitivity to tica-
grelor or any of its components.12 Prasugrel is contra-
indicated in individuals with active pathological
bleeding, prior transient ischemic attack (TIA) or stroke,
or hypersensitivity to prasugrel or any of its compo-
nents.13 Of note, the most recent American Heart Asso-
ciation (AHA)/American College of Cardiology (ACC)
guidelines for patients with NSTE-ACS now recom-
mend ticagrelor over clopidogrel for patients treated
with an early invasive or ischemia-guided strategy,
and prasugrel over clopidogrel in those undergoing
PCI who are not considered to be at high risk of bleed-
ing complications.14
SUBGROUP ANALYSES OF THE
MAJOR CLINICAL TRIALS
A number of subgroup analyses of PLATO, TRITON-
TIMI 38, and TRILOGY-ACS have been performed.
Patients with diabetes mellitus (DM) are known to
have high platelet reactivity and an increased risk of
ischemic events and bleeding post-ACS. In PLATO,
ticagrelor compared with clopidogrel reduced ische-
mic events irrespective of diabetic status and glycemic
control, without an increase in major bleeding
events.15 Diabetic status, however, seemed to be a dif-
ferentiator in TRITON-TIMI 38: the reduction in ische-
mic events observed with prasugrel versus clopidogrel
was numerically greater in patients with DM than in
those without DM, although there was no significant
interaction between treatment effect and diabetes sta-
tus (Pinteraction 5 0.09).
16
The elderly represent another group with an
increased risk of recurrent ischemic events and death.17
In PLATO, the antithrombotic benefits of ticagrelor
applied to both patients aged $75 and ,75 years, with
respect to the composite of cardiovascular death, MI, or
stroke.17 An exploratory post hoc subgroup analysis of
TRITON-TIMI 38 demonstrated that prasugrel had less
clinical efficacy and greater absolute levels of bleeding in
patients aged $75 years than the overall study cohort.3
In TRILOGY-ACS, a reduced maintenance dose of pra-
sugrel (5 mg) in a cohort of 2083 patients aged$75 years
showed no difference in ischemic or bleeding outcomes
compared with clopidogrel. No significant interactions
among weight, pharmacodynamic response in an ex
vivo platelet function substudy, and bleeding risk were
observed between reduced-dose prasugrel and clopi-
dogrel in elderly patients.4
Patients with ACS and a history of stroke or TIA are
known to have an increased rate of recurrent cardiac
events and intracranial hemorrhages,18 as demon-
strated in PLATO.19 Despite the numerical increase
in event rates, the effect of ticagrelor was consistent
with the overall PLATO results and demonstrated
a favorable net clinical benefit and decreased mortal-
ity. TRITON-TIMI 38 also demonstrated a higher rate
of death from cardiovascular causes, nonfatal MI, or
nonfatal stroke in patients with a history of stroke or
TIA, relative to those without.20 The numerical
increase in recurrent cardiac events and intracranial
hemorrhage in these patients resulted in a net harm
from prasugrel (HR: 1.54; 95% CI, 1.02–2.32; P 5 0.04),
and these results were not consistent with the overall
study population.
Patients with STEMI are at greater risk of side effects
as they need to undergo PCI shortly after diagnosis;
oral antiplatelet agents are not fully effective by the
time of PCI and are often delayed until after PCI is
completed.21,22 Results of a subgroup analysis of the
PLATO trial in patients with STEMI or left bundle-
branch block and intended for reperfusion with pri-
mary PCI were consistent with the main results of
the PLATO trial; ticagrelor plus aspirin reduced car-
diovascular and total death, MI, and stent thrombosis
and improved survival without an increase in major
bleeding compared with clopidogrel plus aspirin.21 In
a TRITON-TIMI 38 subgroup analysis of patients with
STEMI undergoing primary PCI (PPCI) or late PCI,
prasugrel plus aspirin was also more effective than
clopidogrel plus aspirin in preventing ischemic events,
without an increase in bleeding.23
Another potential risk is the concomitant use of oral
antiplatelet agents and proton pump inhibitors (PPIs),
although available data are conflicting.24 Previous
studies have shown that certain PPIs reduce platelet
inhibition when administered with clopidogrel.24
Results of a subanalysis of the PLATO trial demon-
strated that PPI use was independently associated
with a higher rate of cardiovascular events in patients
receiving both clopidogrel and ticagrelor.25 This anal-
ysis suggests that the association between PPI use and
adverse events in the PLATO trial may be a result of
confounding, and that PPI use is a marker for higher
e1880 Husted and Boersma
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rates of cardiovascular events, as opposed to the cause
of these events. In a TRITON-TIMI 38 subgroup
analysis, no association was found between PPI use
and risk of the composite of cardiovascular death,
MI, or stroke for patients treated with clopidogrel or
prasugrel.26
STUDY PATIENTS
The characteristics of study patients differed between
PLATO, TRITON-TIMI 38, and TRILOGY-ACS. Each
study enrolled patients with ACS, although the target
populations were different (Table 1). PLATO enrolled
a broad spectrum of patients with ACS (NSTE-ACS or
STEMI) who were identified within 24 hours after hos-
pitalization for the index event. Planned treatment
intention (invasive vs. medical management) was pre-
specified by the investigator. No restrictions were
placed on the type of patients with ACS, the propor-
tion of patients with NSTE-ACS or STEMI, pretreat-
ment with clopidogrel, or the prespecified treatment
strategy (PCI or CABG or medical management).
In general, PLATO patients represented a typical
ACS population, as demonstrated by large-scale regis-
try data from European and American practices. In the
Swedish ACS Registry (RIKS-HIA), 64% of patients
from 1998 to 2005 (n 5 205,269) and 79% of patients
from 2007 (n5 24,695) met PLATO inclusion criteria.27
Comparisons of the Global Registry of Acute Coronary
Events (GRACE) with the PLATO patients support
these findings.27,28
TRITON-TIMI 38 enrolled patients with ACS
(NSTE-ACS or STEMI) with planned PCI. Patients
with ACS with planned medical management were
excluded, as were those who had received treatment
with any thienopyridine within 5 days of randomiza-
tion, which were the main differences in design com-
pared with PLATO. In TRITON-TIMI-38, NSTE-ACS
patients were enrolled within 72 hours of symptom
onset and randomization took place on the catheteri-
zation table, immediately before scheduled PCI.
STEMI patients were enrolled within 12 hours of
symptom onset if PPCI was planned, or within 14 days
after receiving medical therapy for STEMI. Recruit-
ment of NSTE-ACS and post-STEMI patients was
restricted to patients whose anatomy was considered
amenable to PCI before randomization, and recruit-
ment of STEMI patients was capped at 26% of the
overall cohort (n 5 3534 enrolled).
During index hospitalization in PLATO, 34% of pa-
tients with ACS were managed medically and 4.5%
underwent CABG2; however, only 1% of patients in
TRITON-TIMI 38 underwent CABG as the index
procedure, as patients with planned CABG were
excluded from this study.3 Furthermore, no patients
were managed medically in TRITON-TIMI 38,
whereas the TRILOGY-ACS study examined the use
of prasugrel within 10 days of an event in NSTE-ACS
patients who were selected for a final treatment strat-
egy of medical management. Patients were also
required to have at least one of the 4 risk criteria:
age of $60 years; presence of DM; previous MI; or
previous revascularization with PCI or CABG.10,29
The primary TRILOGY analysis considered the 7243
patients aged #75 years. Of these, 571 patients
(7.9%) underwent revascularization with PCI, CABG,
or both, during follow-up. A secondary TRILOGY
analysis considered the primary cohort plus an addi-
tional 2083 patients aged $75 years receiving
a reduced maintenance dose of prasugrel 5 mg daily.
Initially, data from the STEMI cohort of PLATO and
TRITON-TIMI 38 may seem suitable for comparison.
However, the PLATO analysis included patients with
persistent ST-elevation and planned PPCI (defined as
PCI within 24 hours of symptom onset) or new
bundle-branch block and planned PPCI.21,30 In con-
trast, in TRITON-TIMI 38, the subanalysis of STEMI
patients included data from patients who underwent
PPCI (n 5 2438; within 12 hours of symptom onset)
and those who underwent secondary PCI (n 5 1094;
between 12 hours and 14 days of symptom onset), as
prespecified in the protocol.23,31
As the TRITON-TIMI 38 study was exclusively in-
terventional, the overall proportion of patients receiv-
ing a stent (95%) was higher than in PLATO (61%).
Moreover, the proportion of the overall study popula-
tion receiving drug-eluting stents (DES) versus bare-
metal stents (BMS) differed between PLATO (DES 5
19%; BMS 5 42%), and TRITON (DES 5 47%; BMS 5
48%).2,3 The type of stent (DES vs. BMS) deployed may
be particularly relevant due to other differences
in study design between PLATO and TRITON-TIMI
38. For example, as patients in TRITON-TIMI 38
were randomized “on the catheterization table,”
clopidogrel-mediated inhibition of platelet aggregation
may not have been established by the time of interven-
tion. This may have contributed to the high rate of
periprocedural events reported in TRITON-TIMI 38
(independent of treatment, 69% of all cardiovascular
events occurring in the first 30 days of TRITON were
periprocedural). In fact, in the ONSET/OFFSET study
of 123 patients with stable coronary artery disease
receiving either clopidogrel (600 mg loading dose, 75
mg/d maintenance dose) or ticagrelor (180 mg loading
dose, 90 mg twice-daily maintenance dose), plus aspi-
rin (75–100 mg/d), the time to maximum inhibition of
platelet aggregation was nearly 7.8 hours after the
Ticagrelor and Prasugrel Trials in ACS e1881
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loading dose for clopidogrel, whereas it took 2 hours
after the loading dose for ticagrelor.32 As such, in this
scenario a DES (vs. BMS) may be more beneficial in
protecting against cardiovascular events.33 The type of
stent may also be important when it comes to risk of
late stent thrombosis. The incidence of stent thrombo-
sis within 1 year of DES or BMS deployment is similar
given patients also receive the recommended dual
antiplatelet therapy of aspirin plus a P2Y12 receptor
inhibitor for $12 months.34 However, there may be
a slight increase in risk for late stent thrombosis
(thrombosis occurring after 1 year of deployment) with
DES partially due to delayed neointimal coverage.35
In some respects, the baseline characteristics
of PLATO, TRITON-TIMI 38, and TRILOGY-ACS
patients were similar. However, there were also some
notable differences. TRILOGY-ACS, for example, only
enrolled patients with NSTE-ACS, whereas approxi-
mately 9% of PLATO patients intended for noninva-
sive management were diagnosed with STEMI at
discharge. Also, approximately, a third of PLATO pa-
tients intended for noninvasive management actually
underwent PCI or CABG during follow-up, whereas
only 7.9% of the primary TRILOGY cohort underwent
revascularization during follow-up.
Current guidelines (Table 2) for the treatment of
ACS reflect the different inclusion criteria and patient
populations of PLATO and TRITON-TIMI-38. The
European Society of Cardiology (ESC) NSTE-ACS
guidelines37 and the AHA/ACC NSTE-ACS guide-
lines14 have been revised recently (Table 2). Although
the levels of evidence for the use of prasugrel
and ticagrelor are the same (level 1B), ticagrelor is rec-
ommended regardless of initial treatment strategy
(including patients pretreated with clopidogrel),
whereas prasugrel is limited to P2Y12 inhibitor–naive
patients (especially patients with diabetes) with
known coronary anatomy and who are proceeding to
PCI unless there is a high risk of life-threatening bleed-
ing or other contraindications. The revised ESC STEMI
guidelines38 also recommend the use of ticagrelor and
prasugrel (both evidence level 1B). The use of prasu-
grel is restricted to patients who are clopidogrel naive
without an increased risk of bleeding (Table 2).
Prasugrel is suitable for a specific population of pa-
tients with ACS, as supported by a recent subanalysis
of the TRITON-TIMI 38 data20 and by the recent
TRILOGY-ACS study.10 The efficacy and safety of pra-
sugrel was examined in a “core clinical cohort” (n 5
10,804, 79% of TRITON-TIMI 38 patients), which
excluded patients without a net clinical benefit because
of an increased risk of bleeding complications (patients
$75 years, ,60 kg or with prior history of stroke or
TIA). Patients receiving prasugrel had a clinically
significant decrease in the primary end point of cardio-
vascular death, MI, or stroke compared with those
receiving clopidogrel (8.3 vs. 11.0%; HR: 0.74; 95%
CI, 0.66–0.84; P , 0.0001). However, patients $75
years and ,60 kg (n 5 2149, 16%) receiving prasugrel
versus clopidogrel did not show a significant differ-
ence in efficacy in terms of the primary end point
(15.3% vs. 16.3%; HR: 0.94; 95% CI, 0.76–1.18; P 5
0.61), possibly caused by the increased risk of bleeding
within these subgroups of patients. These patients
received a lower dose of 5 mg in the later TRILOGY-
ACS study (see below). However, it should be noted
that effect estimates in several subgroups have wide
confidence intervals, and the possibility of type II er-
rors should not be ignored. The TRILOGY-ACS study
enrolled patients with unstable angina/NSTEMI for
whom a medical management strategy was selected.
The prasugrel maintenance dose was 10 mg, but was
adjusted to 5 mg for patients who weighed ,60 kg or
were $75 years of age. In patients aged ,75 years,
prasugrel did not significantly reduce the frequency
of death from vascular causes, MI, or stroke compared
with clopidogrel.10 More recently, a subanalysis of
TRILOGY-ACS found that the proportion of patients
who experienced the primary end point was lower
with prasugrel versus clopidogrel for those who had
pre-enrollment angiography (10.7% vs. 14.9%, HR:
0.77; 95% CI, 0.61–0.98; P 5 0.032), but did not differ
between treatment groups in patients who did not
have angiography (16.3% vs. 16.7%, HR: 1.01; 95%
CI, 0.84–1.20; P 5 0.94).41 Of the patients who had
angiography before treatment (n 5 3085) and for
whom CAD data were available, 2885 patients had
at least 1 stenosis of more than 50%; 1892 of these
2885 patients (66%) did not have revascularization
owing to a coronary anatomy that was judged to be
unsuitable or without indication for PCI.41
Based on these results, prasugrel may not be the
most appropriate option for NSTE-ACS patients trea-
ted with an ischemia-guided strategy, although further
studies are warranted to corroborate the findings in
patients who undergo angiography.
THE ACTIVE COMPARATOR:
CLOPIDOGREL
PLATO, TRITON-TIMI 38, and TRILOGY-ACS all
used clopidogrel as the control arm; however, the
use of clopidogrel differed markedly between these
trials. In PLATO, 46% of patients received open-label
clopidogrel before randomization (including loading
dose). Clopidogrel-randomized patients received
a 300 mg loading dose, unless they had received
e1882 Husted and Boersma
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Table 2. International guideline recommendations for oral antiplatelet agents reflect the different patient populations studied in the PLATO and TRITON-
TIMI 38 trials.
Recommendations Class* Level†
ESC/EACTS myocardial revascularization guidelines—Wijns et al36
STEMI Prasugrel‡ I B
Ticagrelor‡ I B
Clopidogrel§ (with 600 mg loading dose as soon as possible) I C
NSTE-ACS Prasugrel‡ IIa B
Ticagrelor‡ I B
Clopidogrel (with 600 mg loading dose as soon as possible) I C
Clopidogrel (for 9–12 mo after PCI) I B
ESC NSTE-ACS guidelines—Hamm et al37
A P2Y12 inhibitor should be added to aspirin as soon as possible and maintained over 12 mo, unless there are
contraindications such as excessive risk of bleeding
I A
Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended for all patients at moderate-to-high risk
of ischemic events (eg, elevated troponins), regardless of initial treatment strategy and including those
pretreated with clopidogrel (which should be discontinued when ticagrelor is commenced)
I B
Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended for P2Y12 inhibitor–naive patients
(especially patients with diabetes) in whom coronary anatomy is known and who are proceeding to PCI
unless there is a high risk of life-threatening bleeding or other contraindications.
I¶ B
Clopidogrel (300 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive
ticagrelor or prasugrel
I A
AHA/ACC NSTE-ACS guidelines—Amsterdam et al14
Aspirin
Non–enteric-coated aspirin to all patients promptly after presentation 162–325 mg I A
Aspirin maintenance dose continued indefinitely 81–162 mg/d I A
P2Y12 inhibitors
Clopidogrel loading dose followed by daily maintenance dose in
patients unable to take aspirin
75 mg I B
P2Y12 inhibitor, in addition to aspirin, for up to 12 mo for patients
treated initially with either an early invasive or initial ischemia-guided
strategy
I B
Clopidogrel 300 mg or 600 mg loading dose,
then 75 mg/d
Ticagrelork 180 mg loading dose, then 90 mg
twice daily
P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) continued
for at least 12 mo in post-PCI patients treated with coronary stents
NA I B
(Continued on next page)
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Table 2. (Continued) International guideline recommendations for oral antiplatelet agents reflect the different patient populations studied in the PLATO and
TRITON-TIMI 38 trials.
Recommendations Class* Level†
Ticagrelor in preference to clopidogrel for patients treated with an early
invasive or ischemia-guided strategy
NA IIa B
ESC STEMI guidelines—Steg et al38
An ADP-receptor blocker is recommended in addition to aspirin. Options are I A
Prasugrel in clopidogrel-naive patients, if no history of prior stroke/TIA, age ,75 yrs I B
Ticagrelor I B
Clopidogrel, preferably when prasugrel or ticagrelor are either not available or contraindicated I C
ACCP secondary prevention guidelines—Vandvik et al39
For patients in the first year after an ACS who have
not undergone PCI—dual antiplatelet therapy
Ticagrelor 90 mg twice daily plus low-dose aspirin
75–100 mg daily rather than single antiplatelet
therapy
I B
Clopidogrel 75 mg daily plus low-dose aspirin 75–100
mg daily rather than single antiplatelet therapy
I B
Ticagrelor 90 mg twice daily plus low-dose aspirin
rather than clopidogrel 75 mg daily plus low-dose
aspirin
II B
For patients in the first year after an ACS who have
undergone PCI with stent placement—dual anti
platelet therapy
Ticagrelor 90 mg twice daily plus low-dose aspirin
75–100 mg daily over single antiplatelet therapy
I B
Clopidogrel 75 mg daily plus low-dose aspirin
75–100 mg daily over single antiplatelet therapy
I B
Prasugrel# 10 mg daily plus low-dose aspirin over
single antiplatelet therapy
I B
Ticagrelor 90 mg twice daily plus low-dose aspirin
over clopidogrel 75 mg daily plus low-dose aspirin
II B
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention—Levine et al40
Patients already taking daily aspirin therapy should take 81–325 mg before PCI I B
Patients not on aspirin therapy should be given nonenteric aspirin 325 mg before PCI I B
After PCI, use of aspirin should be continued indefinitely I A
After PCI, it is reasonable to use aspirin 81 mg per day in preference to higher maintenance doses IIa B
A loading dose of a P2Y12 receptor inhibitor should
be given to patients undergoing PCI with stenting
(Level of evidence 1A). Options include
Clopidogrel 600 mg (ACS and non-ACS patients) I B
Prasugrel 60 mg (ACS patients) I B
Ticagrelor 180 mg (ACS patients) I B
In patients receiving a stent (BMS or DES) during PCI
for ACS, P2Y12 inhibitor therapy should be given for
at least 12 mo. Options include
Clopidogrel 75 mg daily I B
Prasugrel 10 mg daily I B
Ticagrelor 90 mg twice daily I B
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a loading dose of open-label clopidogrel or were tak-
ing clopidogrel (or ticlopidine) for at least 5 days
before randomization. Patients undergoing PCI could
receive an additional 300 mg clopidogrel loading dose
at the discretion of the investigator. Between the time
of the index event and up to 24 hours after randomi-
zation, 19.6% of the clopidogrel control group received
$600 mg clopidogrel.2 In a subset of patients with
STEMI, 35.8% of patients in the clopidogrel group
received a 600 mg total “intended” dose of clopidogrel
(open label and blinded) within the 24-hour period
after the first dose.21 Clopidogrel study drug was
started at a median of 5.3 hours after hospitalization
and a median of 11.3 hours after the onset of chest
pain. Furthermore, the median time from first dose
of study drug to PCI was 0.25 hours for STEMI and
3.65 hours in NSTE-ACS patients.2
In TRITON-TIMI 38, patients were excluded if they
had received clopidogrel within 5 days before PCI, and
all patients randomized to clopidogrel received a load-
ing dose of 300 mg. Although the investigators
acknowledged that there were data supporting the
use of a higher loading dose of clopidogrel, and that
many physicians use a 600-mg loading dose in daily
clinical practice, they concluded that data were insuf-
ficient to justify using a 600-mg loading dose in this
study.31 The loading dose could be given at any time
after randomization, which took place on the catheter-
ization table within 1 hour of the patient leaving the
catheterization laboratory. Clopidogrel study drug
was administered before the first coronary guide wire
was placed in 25% of patients; during PCI or within 1
hour after PCI in 74%; and more than 1 hour after PCI
in 1% of patients.3 The median time from symptom
onset until receiving the loading dose of prasugrel or
clopidogrel study drug was 29.7 hours (range, 17.4–
49.8 hours) in patients with unstable angina/NSTEMI,
due to the protocol-specified delay until after angiog-
raphy, and 7.0 hours (range, 3.7–28.5 hours) in patients
with STEMI.42
Newer studies are providing further insights into
clinical outcomes associated with the timing of the
antiplatelet loading dose. Notably, the ACCOAST
study demonstrated that among patients with NSTE-
ACS who were scheduled to undergo catheterization,
pretreatment with prasugrel at the time of diagnosis
did not reduce the rate of major ischemic events up to
30 days but increased the rate of major bleeding com-
plications, compared with administration in relation to
coronary angiography.43 Furthermore, the results of
the ACCOAST, TRITON, and TRILOGY ACS trials
are cited by the current AHA/ACC NSTE-ACS guide-
lines as the basis of prasugrel not being recommended
for initial therapy in NSTE-ACS patients.14 TheTa
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ATLANTIC study evaluated prehospital administra-
tion of ticagrelor in patients with STEMI, and although
this was safe and reduced stent thrombosis, it did not
demonstrate a significant effect on the primary efficacy
end point of reperfusion.44
In TRILOGY-ACS, 26% of patients initiated clopi-
dogrel treatment with a loading dose of 300–600 mg
and a daily maintenance dose of 75 mg until random-
ization; 70% of patients received clopidogrel treatment
for at least 5 days before randomization and continued
with a 75-mg maintenance dose. Testing for the supe-
riority of prasugrel over clopidogrel was performed
with a 2-sided log-rank test and stratified by clopidog-
rel status at randomization. Notably, a lower loading
dose of prasugrel (30 mg) was used in TRILOGY-ACS
compared with that used in TRITON-TIMI-38 (60 mg)
to test whether there was a reduced risk of acute bleed-
ing in patients who, in the absence of a revasculariza-
tion procedure, did not require immediate high-level
platelet inhibition just after randomization. It is likely
that the timing and initial dosing of study drug admin-
istration are important for the overall trial results.
Therefore, the marked differences in the active com-
parator regime argue strongly against a cross-trial
analysis for the prasugrel and ticagrelor studies.
STUDY END POINTS
The primary end points of PLATO and TRITON-TIMI
38—the composite of death from vascular causes, non-
fatal MI, and nonfatal stroke—are identical. However,
the impact of the different study designs on the ability
to detect periprocedural MIs should be considered.
Because of the short time between randomization
and PCI in PLATO (49% of patients underwent PCI
within 24 hours of randomization), there was gener-
ally only opportunity for 1 measurement of preproce-
dural cardiac ischemia marker level. As 86% of
patients in PLATO had elevated troponin I level at
study entry,2 it was difficult to detect periprocedural
MIs that are based on a “rise and fall” of cardiac bio-
markers. In TRITON-TIMI 38, the end point of nonfatal
MI had to be distinct from the index event.31 Because of
the time allowed between the onset of symptoms and
PCI in this study, at least 2 cardiac biomarker measure-
ments before PCI were generally allowed, and hence,
MI adjudication was less confounded by the index
event (at least in the NSTE-ACS and post-STEMI pa-
tients) than in PLATO. Furthermore, the high percent-
age of PCIs performed in the TRITON-TIMI 38 study
led to a much greater representation of periprocedural
MIs than in PLATO (Table 3).
Approximately, 19% of all MIs in PLATO were spe-
cifically related to a rise in biomarker.47 However,
more than half of the MIs in TRITON-TIMI-38 were
classified as periprocedural, and by definition, classed
as “enzymatic” events (classification by adjudication
of laboratory values only45; Table 3). In TRITON-
TIMI-38, in patients receiving at least 1 coronary stent
(94% of the study patients), 65% of events occurred
within the first 30 days, and of these, 69% were
periprocedural.48 Overall, 46% (median follow-up,
14.5 months) were classified as periprocedural. Despite
the large number of biomarker-defined events in
TRITON-TIMI 38, the net clinical benefit of prasugrel
(in terms of the primary composite efficacy and safety
end point) was maintained when periprocedural MIs
were excluded from the analysis.48
The bleeding definitions also differed between stud-
ies: PLATO used both the PLATO-defined bleeding and
TIMI bleeding definitions (although TIMI bleeding was
derived from nonadjudicated events); TRITON-TIMI 38
used the TIMI bleeding definition; and TRILOGY-ACS
used TIMI and Global Utilization of Streptokinase and t-
PA for Occluded Coronary Arteries (GUSTO) defini-
tions. Although Becker et al5 reported comprehensive
bleeding results from PLATO, including data described
Table 3. Summary of periprocedural MIs by trial.45,46
Study Drug Type 4a* (%) Type 4b† (%)
PLATO‡ Ticagrelor 99/504 (19.6) 69/504 (13.7)
Clopidogrel 124/593 (20.9) 103/593 (17.4)
TRITON-TIMI 38 Prasugrel 279/497 (56.1)§ 48/497 (9.7)¶
Clopidogrel 321/659 (48.7)§ 107/659 (16.2)¶
Data are presented as number of MIs in subgroup/total number of MIs per treatment arm.
*Type 4a 5 MI associated with PCI.
†Type 4b 5 MI with stent thrombosis as documented by angiography or at autopsy (all type 4 events are PCI related).
‡All suspected MI events were adjudicated by a Clinical Events Committee; silent MI events were excluded.46
§Prasugrel versus clopidogrel HR, 0.86 (95% CI, 0.74–1.01), P 5 0.07.
¶Prasugrel versus clopidogrel HR, 0.45 (95% CI, 0.32–0.63), P , 0.001.
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according to various definitions, cross-trial comparison
of bleeding data is still not recommended due to the
other confounding factors discussed above.
CONCLUSIONS
The marked differences in study designs, patient pop-
ulations and characteristics, assessment of end points,
and loading dose of the comparator clopidogrel in
PLATO, TRITON-TIMI 38, and TRILOGY-ACS render
cross-trial comparisons inappropriate. Recent ESC up-
dates to the NSTE-ACS and STEMI guidelines clearly
reflect the differences between TRITON-TIMI 38 and
PLATO. NSTE-ACS guidelines recommend the use of
ticagrelor irrespective of initial treatment, including use
in patients pretreated with clopidogrel. The guidelines
limit the recommendation of prasugrel to P2Y12 inhibi-
tor–naive patients with known coronary anatomy and
who are proceeding to PCI, unless there are other com-
plications or a high risk of life-threatening bleeding.14,37
The updated ESC STEMI guidelines also recommend
use of either ticagrelor or prasugrel; however, prasugrel
is only recommended for clopidogrel-naive patients
who are not at increased risk for bleeding.38
Analysis of PLATO and TRITON-TIMI 38 indicates
that the composite of efficacy and safety demonstrated
statistically significant superiority of ticagrelor and
prasugrel, respectively, over clopidogrel control.2,3,9,11
The design of TRILOGY-ACS, which included a lower
dose of prasugrel to reduce bleeding risk in elderly
patients and those with a low body weight, may have
contributed to the fact that the study failed to demon-
strate superiority of prasugrel compared with clopi-
dogrel in medically managed NSTE-ACS patients.4,10
In general, indirect comparison meta-analyses
adjusted by reference to a control that was used dif-
ferently between trials are vulnerable to bias.
Given the differences between PLATO, TRITON-
TIMI 38, and TRILOGY-ACS described above, in our
view, cross-trial comparisons cannot be made appro-
priately. Clinicians therefore need to carefully evaluate
the data from each of these trials to decide which oral
antiplatelet agent is most appropriate for a particular
patient and their condition.
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